Abstract: An integrated assembly includes a switchgear apparatus configured for operation at voltages up to 72.5 kV and a mount assembly configured for coupling to a pole and to support the switchgear apparatus from the pole. The mount assembly includes a crossbar, a pole mount configured for coupling to the pole and to be secured to the crossbar at different positions along a length of the crossbar, a mounting bracket configured to support the switchgear apparatus on the crossbar, and a pair of crossbar mounts configured to be secured to the mounting bracket for supporting the mounting bracket on the crossbar at different positions along the length of the crossbar. The mounting bracket includes a pair of flanges that can be secured to either the pair of crossbar mounts or a pole mount bracket configured to support the mounting bracket on the pole.

Abstract: There are methods for treating hidradenitis suppurtiva using compounds and analogues that inhibit certain kinases, including Janus Kinase (JAK).

Abstract: Embodiments of the present disclosure provide methods, systems, apparatuses, and computer program products that enable client devices to install integrations of a third party application that supports variable host address identification.

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A? and A? are independently O, C?O, C—R? or N—R?, where R? and R? may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R? may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A? and A? is O or C?O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsu

Abstract: A turbomachine component includes a platform, a shank, and an airfoil. The platform includes a pressure side slash face and a suction side slash face. The shank extends radially inward from the platform. The airfoil extends radially outward from the platform. The airfoil includes a leading edge and a trailing edge. A cooling circuit is defined within the shank and the airfoil. The cooling circuit further includes a plurality of exit channels disposed along the trailing edge of the airfoil. The cooling circuit further includes at least one bypass conduit that extends from an inlet disposed in the cooling circuit to an outlet positioned on the pressure side slash face. The at least one bypass conduit being positioned radially inward of the plurality of exit channels.

Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5?-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Abstract: An integrated assembly includes a switchgear apparatus for operation at voltages up to 72.5 kV and a mount assembly for coupling to a pole and to support the switchgear apparatus. The mount assembly includes a crossbar, a pole mount, a mounting bracket to support the switchgear apparatus, and a pair of crossbar mounts for supporting the mounting bracket on the crossbar at different positions. Each crossbar mount includes a first arm, a second arm spaced from the first arm and extending parallel to the first arm, a third arm extending between and coupled to a distal end of each of the first and second arms, and a flange extending between and coupled to a proximal end of each of the first and second arms. The flange extends parallel to the third arm. The first, second, and third arms and the flange form an enclosed space to receive the crossbar.

Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.

Abstract: Home telematics devices are engineered to identify unique device signatures for all appliances, fixtures, and so on that generate voltage noise, pressure waves, and acoustic responses throughout a property. The device signatures comprise the inventory of devices in the insured's home and are used to create an electronic record of the devices that assists him in filing a claim with an insurer that is quick and easy after a theft or total loss. Using the device signatures provided by home telematics devices' sensing an itemization technology, fraud detection is also possible. Additionally, analytics software predicts possible failure by analyzing the device signatures.

Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: A compound having the structures: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy and —(CH2)m—W, where W is C3-C8 cycloalkyl, bicycloalkyl, bridged bicycloalkyl, phenyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said alkyl, cycloalkyl, alkoxy, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, halo, cyano, deuterium, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, —SO2—R?, —CONR?R?, NR?COR?, —NR?CONR?R?, —NR?CO2R?, —(CH2)n—SO2—R?, —NHSO2—R?, —NR?SO2—R?, —SO2NR?R?, NR?R? or SR? where R? and R? are independently H, C1-C6 alkyl or C3-C8 cycloalkyl; R1 selected from the group consisting of phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two, three or four heteroatoms se

Abstract: Disclosed herein is a method and apparatus for automatic extrudate loading and alignment. An extrudate handling system includes a head end assembly and an imaging device (which may be part of the head end assembly). The imaging device is configured to image an end face of an extrudate, and generate, during translation of the extrudate, an imaging output signal indicative of a rotational position of the end face of the extrudate. The head end assembly includes a rotational effector to rotate the extrudate during translation thereof and a fixed effector rotationally fixed relative to a track. The extrudate handling system is able to determine the rotational position of the web angle of the extrudate and precisely adjust the rotational position while linearly translating the extrudate along the track. The extrudate handling system provides greater accuracy, reduced costs, and improved results.

Abstract: This patent document relates to systems, structures, devices, and fabrication processes for ceramic matrix composites suitable for use in a nuclear reactor environment and other applications requiring materials that can withstand high temperatures and/or highly corrosive environments. In one exemplary aspect, a method of joining and sealing ceramic structures is disclosed. The method comprises forming a joint of a ceramic structure and an end plug using a sealing material, wherein the end plug has a hole that goes through a top surface and a bottom surface of the end plug; filling the ceramic structure with a desired gas composition through the hole; heating a material into a molten form using a heat source; and directing the material into the hole, wherein the material solidifies to seal the end plug.

Abstract: The invention relates to benzimidazoles of Formula (1) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: The description relates to artificial intelligence assisted wearables, such as backpacks. An example backpack may include sensors, such as a microphone and a camera. The backpack may receive a contextual voice command from a user. The contextual voice command may include a non-explicit reference to an object in an environment. The backpack may use the sensors to sense the environment, use an artificial intelligence engine to identify the object in the environment, and use a digital assistant to perform a contextual task in response to the contextual voice command. The contextual task may relate to the object in the environment. The backpack may output a response to the contextual voice command to the user.

Abstract: A tip shroud includes a pair of opposed, axially extending wings configured to couple to an airfoil at a radially outer end thereof. The tip shroud also includes a tip rail extending radially from the pair of opposed, axially extending wings. Tip shroud surface profiles may be of the downstream and/or upstream side of the tip rail, a leading Z-notch of the tip shroud, and/or downstream radially inner surface of a wing. The surface profiles may have a nominal profile substantially in accordance with at least part of Cartesian coordinate values of X and Y, and perhaps Z and a thickness, set forth in a respective table. The radially inner surface of the wing may define a protrusion extending along the radially outer end of the airfoil, the suction side fillet, and a radial inner surface of the wing to an axial edge of the wing.

Abstract: Systems and methods provide managing of communication between a remote data object hosted by a remote resource and a group-based communication interface of a group-based communication system.

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.